{"entity":{"id":"nct07290088","kind":"trial","name":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","aka":[],"tldr":"A phase 2/3 trial of PRL3-ZUMAB in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, now recruiting.","summary":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients is a phase 2/3 interventional study registered as NCT07290088 by Intra-IMMUSG Pte Ltd, with 52 participants planned, started 2023-01-09 and due to reach its primary completion in 2026-12. Interventions recorded: PRL3-ZUMAB.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07290088","url":"https://clinicaltrials.gov/study/NCT07290088"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["intra-immusg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07290088","phase":"2/3","setting":"An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients","sponsor":"Intra-IMMUSG Pte Ltd","enrolled":52,"outcomes":[]},"route":"/trials/nct07290088/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/"}]}}